

ASX RELEASE  
22 January 2021

## **KAZIA PRESENTS TO SHARECAFE “HIDDEN GEMS” WEBINAR**

**Sydney, 2 January 2021** – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide a copy of the presentation to be made by our CEO, Dr James Garner to the Share Cafe Webinar - Micro/Small Cap "Hidden Gems" Webinar to be held today (Friday 22 January 2021) from 12:30pm AEDT / 9:30am AWST.

This webinar is able to be viewed live via Zoom over the internet and will provide viewers the opportunity to hear from, and engage with, a range of ASX-listed leading micro/mid cap companies.

To access further details of the event and to register (no charge), please copy and paste the following link into your internet browser:

[https://us02web.zoom.us/webinar/register/WN\\_i4IClnYTAqNPdi1Rd8Hkg](https://us02web.zoom.us/webinar/register/WN_i4IClnYTAqNPdi1Rd8Hkg)

### **About Kazia Therapeutics Limited**

Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.

Our lead program is paxalisib (formerly GDC-0084), a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib entered GBM AGILE, a pivotal study in glioblastoma, in October 2020. Seven additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020.

TRX-E-002-1 (Cantrixil) is a third generation benzopyran molecule with activity against cancer stem cells and is being developed to treat ovarian cancer. TRX-E-002-1 has completed a phase

### **Board of Directors**

**Mr Iain Ross** Chairman, Non-Executive Director

**Mr Bryce Carmine** Non-Executive Director


**Mr Steven Coffey** Non-Executive Director

**Dr James Garner** Chief Executive Officer, Managing Director

I clinical trial in Australia and the United States. Cantrixil was granted orphan designation for ovarian cancer by the US FDA in April 2015.

For more information, please visit [www.kaziatherapeutics.com](http://www.kaziatherapeutics.com).

This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Managing Director.



**KAZIA**  
THERAPEUTICS



A company developing  
innovative, high-impact  
drugs for cancer

Presentation to ShareCafe  
'Hidden Gems'

Dr James Garner  
Chief Executive Officer & Managing Director




21 January 2021

# Forward-Looking Statements

This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of customer acceptance of existing and new products and services and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to sales, future international, national or regional economic and competitive conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products and services, marketing existing products and services update the forward-looking information contained in this presentation.

# Corporate Overview



 <b>Company Description</b>	Oncology-focused, late-clinical-stage, small-molecule biotechnology company, headquartered in Sydney, Australia
 <b>Pipeline</b>	<b>Paxalisib</b> – brain-penetrant PI3K / mTOR inhibitor in pivotal study for glioblastoma <b>Cantrixil</b> – cancer stem cell-targeting agent in phase I for ovarian cancer
 <b>Financials</b>	Listed on ASX (KZA) and NASDAQ (KZIA) with a market capitalization of ~AU\$ 165 million ~US\$ 20M financing round completed October 2020

# Investment Rationale

## World-Class Asset in Brain Cancer

- Paxalisib developed by Genentech, the world's most successful cancer drug company
- Well-proven mechanism of action, with unique differentiating factor of brain penetration
- Strong scientific rationale for development in brain cancer
- Encouraging clinical data emerging from US-based phase II study
- Potential best-in-class toxicity profile

## Clear Path to Commercialisation

- Ongoing FDA-endorsed GBM AGILE study will serve as pivotal study for registration
- US\$ 1.5 billion pa commercial opportunity in glioblastoma, with potential upside in other cancers
- High unmet medical need – existing standard of care ineffective in two-thirds of patients
- 6x additional clinical studies at top tier US hospitals provide multiple shots on goal
- Optimised regulatory position with Orphan, Fast Track, and Rare Paediatric Disease Designations


## Strong Corporate Story

- Kazia is a late-clinical-stage company, funded for phase III, with one of the leading assets in the global glioblastoma pipeline, and the potential to address a \$1.5 billion market
- Highly-efficient operating model, with ~80% of expenditure applied directly to R&D
- Lean team of internationally-experienced drug developers
- Good potential for partnering and / or M&A during remaining development of paxalisib

# Strong progress was made in 4Q CY2020

<b>September 2020</b>	<b>Agreement with Dana-Farber Cancer Institute to launch new study in PCNSL</b>	Further expansion of clinical program validates paxalisib and potentially expands future use
<b>October 2020</b>	<b>Oversubscribed funding round raised AU\$ 25 million</b>	Funding allows immediate commencement of pivotal study
<b>November 2020</b>	<b>Positive data read-out from phase II glioblastoma study</b>	Greater confidence in paxalisib supports transition to a pivotal study
<b>December 2020</b>	<b>LOI with Pacific Pediatric Neuro-Oncology Consortium for phase II DIPG study</b>	Builds on phase I study at St Jude to advance paxalisib in childhood brain cancer
<b>January 2021</b>	<b>First site opens to paxalisib in GBM AGILE pivotal study</b>	Kazia is now a 'phase III company'

# Latest phase II data compares well to historical data for temozolomide (existing standard of care)



Note: figures for existing therapy are for temozolomide, per Hegi et al. (2005); comparison between different studies is never perfectly like-for-like



# A broad-based clinical program is underway across multiple forms of brain cancer

## Paxalisib (GDC-0084)

### Primary Brain Cancer (brain cancer that begins in the brain)

### Secondary Brain Cancer (brain cancer that spreads from elsewhere in the body)

#### Glioblastoma

Most common and most aggressive brain tumour

Phase II

[NCT03522298](#)



#### Glioblastoma

Pivotal study for FDA registration

Phase II / III

[NCT03970447](#)



#### DIPG

Highly aggressive childhood brain tumour

Phase I

[NCT03696355](#)



#### Primary CNS Lymphoma

Treatment-resistant brain cancer

Phase II

TBD



#### Brain Metastases

Cancer that has spread from any primary tumour

Phase II

[NCT03994796](#)



#### Breast Cancer Brain Mets

(combination with Herceptin®)

Phase II

[NCT03765983](#)



#### Brain Metastases

(combination with radiotherapy)

Phase I

[NCT04192981](#)



Funded by Kazia

Funded Primarily Through Partnerships and External Funding



# Positive newsflow has supported revaluation of Kazia as paxalisib moves towards commercialisation



<b>Market Capitalisation</b>	~AU\$ 165 million										
<b>Shares on Issue</b>	~126 million										
<b>Listing</b>	ASX: KZA NASDAQ: KZIA (1:10 ratio)										
<b>Key Shareholders</b>	<table border="0"> <tr> <td>Willoughby Capital</td> <td>16%</td> </tr> <tr> <td>Platinum Asset Mgmt.</td> <td>9%</td> </tr> <tr> <td>Quest Asset Partners</td> <td>9%</td> </tr> <tr> <td>UniSuper</td> <td>6%</td> </tr> <tr> <td>Board &amp; Mgmt.</td> <td>2%</td> </tr> </table>	Willoughby Capital	16%	Platinum Asset Mgmt.	9%	Quest Asset Partners	9%	UniSuper	6%	Board & Mgmt.	2%
Willoughby Capital	16%										
Platinum Asset Mgmt.	9%										
Quest Asset Partners	9%										
UniSuper	6%										
Board & Mgmt.	2%										
<b>Balance Sheet (AU\$)</b> (as at 30 Sept 20)	<table border="0"> <tr> <td>Cash:</td> <td>\$6.5 million</td> </tr> <tr> <td>FY20 Spend:</td> <td>\$12.5 million</td> </tr> <tr> <td>Runway:</td> <td>2Q CY2021</td> </tr> <tr> <td>Efficiency:</td> <td>~80% R&amp;D</td> </tr> </table>	Cash:	\$6.5 million	FY20 Spend:	\$12.5 million	Runway:	2Q CY2021	Efficiency:	~80% R&D		
Cash:	\$6.5 million										
FY20 Spend:	\$12.5 million										
Runway:	2Q CY2021										
Efficiency:	~80% R&D										

*Note: AU\$ 25 million financing completed in October 2020*

Note: as at 31 December 2020, unless otherwise noted

# Key Objectives for CY2021



Execute on GBM AGILE study



Drive data from broader paxalisib program



Intensify partnering activity



Commence 'rolling NDA' filing activities

# Key Milestones and Anticipated Newsflow

Execution of definitive agreement with GCAR for GBM AGILE pivotal study	October 2020	✓
Further interim data from Kazia phase II glioblastoma trial	November 2020	✓
Initial interim data from phase I DIPG trial at St Jude	November 2020	✓
Commencement of recruitment to GBM AGILE pivotal study in glioblastoma	Q1 CY2021	✓
Initial interim data from phase II BCBM trial at Dana-Farber	H1 CY2021	
<i>Commencement of recruitment to PNOG combination study in DIPG</i>	<i>H1 CY2021</i>	
<i>Commencement of recruitment to phase II PCNSL study at Dana-Farber</i>	<i>H1 CY2021</i>	
Half-Year Financial Report	Q1 CY2021	
Initial interim data from phase II brain mets study by Alliance Group	H1 CY2021	
Initial interim data from phase I brain mets study at Sloan-Kettering	H1 CY2021	
Final data from Kazia phase II glioblastoma trial	H1 CY2021	

*italics* - updated

Note: all guidance is indicative, and subject to amendment in light of changing conference schedules, operational considerations, etc.



**KAZIA**  
THERAPEUTICS

[www.kaziatherapeutics.com](http://www.kaziatherapeutics.com)